查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015197

兒童疫苗市場：依疫苗類型、疾病、技術、最終用戶和年齡層別分類－2026-2032年全球市場預測

Pediatric Vaccines Market by Vaccine Type, Disease, Technology, End User, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，兒童疫苗市值將達到 476.6 億美元，到 2026 年將成長至 509.8 億美元，到 2032 年將達到 797.2 億美元，複合年成長率為 7.62%。

主要市場統計數據
基準年 2025 476.6億美元
預計年份：2026年 509.8億美元
預測年份 2032 797.2億美元
複合年成長率 (%) 7.62%

本導言概述了影響現代兒童疫苗策略的相互關聯的因素：創新、政策、供應韌性和相關人員的期望。

兒童疫苗接種仍然是現代最重要的公共衛生措施之一，背後是臨床科學、公共、採購系統和生產能力之間的複雜相互作用。過去十年，抗原設計、結合技術和聯合製劑的進步擴大了嬰幼兒、兒童和青少年的預防範圍，人們期望透過減少劑量和簡化接種程序來獲得更廣泛的保護。同時，不斷變化的流行病學情況、不斷提高的家長期望以及支付方優先事項的轉變，正迫使疫苗相關人員重新評估供應的韌性和價值提案。

對重塑兒童疫苗研發、生產和管理趨勢的關鍵技術、監管和交付模式轉變進行分析概述。

在兒童疫苗領域，技術突破、政策重點的轉變以及新的供應模式正在推動一場變革，全面重新定義預防措施的設計、生產和交付方式。重組和結合技術的進步擴大了抗原覆蓋範圍並提高了免疫抗原性，使得聯合疫苗的引入成為可能，從而減少就醫次數並簡化免疫接種程序。同時，製造商正在採用模組化和靈活的生產方式，以快速回應需求波動並支援本地供應鏈。

本報告冷靜地評估了近期關稅措施對供應鏈決策、籌資策略以及兒童疫苗生產基地地理分佈的影響。

2025年宣布的貿易政策變化，特別是影響藥品和生物製藥原料的新關稅措施，對兒童疫苗價值鏈產生了累積影響，加劇了成本壓力，促使供應商多元化，並加速了關於近岸外包的討論。特種佐劑、無菌灌裝耗材和一次性生物反應器組件等原料已成為採購團隊尋求替代籌資策略以降低關稅風險的重點。因此，製造商和負責人已重新審視合約條款和庫存策略，以確保免疫接種計劃的持續實施。

將產品類型、目標疾病、技術、終端用戶管道和年齡層與策略、臨床和商業性意義聯繫起來的全面細分洞察。

細分市場分析揭示了產品、疾病、技術、最終用戶和年齡層等因素如何影響整個兒童免疫規劃的開發和實施。根據疫苗類型，市場分為六價疫苗、單價疫苗、五價疫苗和四價疫苗，並進行相應研究。聯合疫苗（例如六價疫苗）優先考慮接種方案的便利性和縮短接種程序，而單價疫苗在針對性疫情應對和加強免疫策略中仍具有重要的戰略意義。疾病特異性分析涵蓋了百白破疫苗、B型肝炎疫苗、b型流感嗜血桿菌疫苗、麻疹疫苗、肺炎鏈球菌疫苗、脊髓灰質炎和輪狀病毒疫苗的市場。其中，百白破疫苗還涉及白喉、百日咳和破傷風，並進行了更詳細的分析。疾病特異性動態，例如肺炎球菌疾病的血清型多樣性和輪狀病毒的基因型變異，為抗原選擇和監測優先順序的確定提供了關鍵資訊。

影響疫苗取得和供應的全球監管協調、生產能力和專案優先事項的區域詳細資訊。

區域趨勢對疫苗策略具有決定性影響，影響美洲、歐洲、中東和非洲以及亞太地區的製造地、監管時間表和專案部署優先事項。在美洲，監管的柔軟性和完善的免疫基礎設施支援聯合製劑的快速部署，而公共和私人支付方越來越重視基於價值的採購和供應鏈機制。北美和拉丁美洲的供應鏈中心也在優先考慮低溫運輸最佳化和數據驅動的疫苗接種率監測，以縮小都市區差距。

從企業層面的策略觀點，揭示製造商如何協調技術投資、供應鏈韌性和相關人員夥伴關係，以保持其在兒童疫苗領域的領先地位。

兒童疫苗領域的企業策略正趨向三大優先主題：技術差異化、供應鏈韌性以及與公共衛生系統的合作。領先的生技藥品公司正投資拓展其聯合疫苗和結合疫苗的產品組合，同時提升其在重組和次單元平台方面的能力，以實現抗原更新和規模化生產。同時，各企業也積極提升產能，包括採用模組化灌裝和包裝生產線以及建立地理位置分散的製造地，以降低中斷風險並滿足各國特定的採購要求。

透過整合產品創新、供應多樣化、定價策略和相關人員合作，促進永續兒童免疫接種成果的實用建議。

產業領導企業應推動一系列合作舉措，將創新、嚴格管理和相關人員協作相結合，以改善兒童疫苗的可及性和專案成效。首先，他們應優先研發聯合疫苗和結合疫苗，以降低接種複雜性並提高依從率，同時確保對生產製造的投資能夠支持跨多個平台的靈活生產。其次，他們應投資於多元化的籌資策略和區域性生產方案，以保護專案免受外部貿易衝擊，並滿足本地供應的採購需求。

透明的調查方法，解釋了主要訪談、第二手資料整合以及用於得出關於兒童疫苗趨勢的檢驗見解的分析安全措施。

本執行摘要的研究基礎是將關鍵相關人員的見解與嚴謹的二手資料研究結合，以確保研究結果的平衡性和檢驗。主要數據是透過對疫苗研發人員、生產經理、採購專家、臨床專案經理和政策制定者的結構化訪談收集的，從而提供了關於供應鏈限制因素、監管重點和部署障礙的背景觀點。這些定性資訊與監管指導文件、疫苗技術方面的同行評審文獻、公開的公司產能投資報告以及全球免疫規劃報告等二手資料進行了交叉比對，以檢驗觀察到的趨勢。

簡明扼要地總結了影響兒童免疫接種成功的技術可能性、操作限制和策略重點。

總之，兒童疫苗正處於快速發展的科學技術與持續存在的實際操作現實的交會點。結合疫苗、重組疫苗和聯合疫苗的技術進步為簡化免疫接種程序和擴大覆蓋範圍提供了清晰的路徑，但計畫實施取決於可靠的供應、監管的完整性和公眾的持續信任。貿易政策趨勢和關稅波動凸顯了部分全球供應鏈的脆弱性，促使企業投資於區域生產能力。這很可能導致未來幾年採購關係和監管合作的重組。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：兒童疫苗市場：依疫苗類型分類

  • 六價
  • 單價
  • 五價
  • 四價

第9章：兒童疫苗市場：依疾病分類

  • DTP
    • 白喉
    • 百日咳
    • 破傷風
  • B型肝炎
  • Hib
  • 麻疹
  • 肺炎球菌
  • 脊髓灰質炎
  • 輪狀病毒

第10章：兒童疫苗市場：依技術分類

  • 組合型
    • 多醣結合型
    • 蛋白質結合型
  • 失活
    • 類毒素
    • 病毒性的
  • 減毒活病毒疫苗
    • 細菌
    • 病毒性的
  • 重組
    • 哺乳動物細胞培養
    • 酵母衍生的
  • 次單元
    • 胜肽次單元
    • 蛋白質次單元

第11章：兒童疫苗市場：依最終用戶分類

  • 診所
    • 一般診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 疫苗接種中心
  • 藥局
    • 醫院藥房
    • 零售藥房

第12章：兒童疫苗市場：依年齡層別分類

  • 青春期
  • 兒童
  • 嬰兒
  • 新生
  • 嬰兒

第13章：兒童疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章兒童疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章兒童疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：兒童疫苗市場

第17章 中國：兒童疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca plc
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • GlaxoSmithKline plc（GSK）
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-030EE4851566

The Pediatric Vaccines Market was valued at USD 47.66 billion in 2025 and is projected to grow to USD 50.98 billion in 2026, with a CAGR of 7.62%, reaching USD 79.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.66 billion
Estimated Year [2026] USD 50.98 billion
Forecast Year [2032] USD 79.72 billion
CAGR (%) 7.62%

A focused introduction outlining the intersecting forces of innovation, policy, supply resilience, and stakeholder expectations that define modern pediatric vaccine strategies

Pediatric vaccination remains one of the most consequential public health interventions of the modern era, underpinned by complex interactions among clinical science, public policy, procurement architecture, and manufacturing capability. Over the past decade, advances in antigen design, conjugation techniques, and combination formulations have expanded the preventive toolkit for infants, toddlers, children, and adolescents, raising expectations for broader protection with fewer injections and simpler schedules. At the same time, evolving epidemiology, heightened parental expectations, and shifting payer priorities have pushed vaccine stakeholders to re-evaluate supply resilience and value propositions.

Consequently, leaders across manufacturing, distribution, and public health institutions must reconcile rapid technological progress with persistent operational realities. Cold chain integrity, regulatory alignment across jurisdictions, and the economics of combination products all influence the feasibility of programmatic uptake. Therefore, a pragmatic introduction to this landscape needs to foreground how innovation translates into deployable solutions, while acknowledging the systemic constraints that shape adoption and access. This summary sets the stage for a deeper examination of the transformative shifts, segmentation nuances, regional differentials, and recommended actions that will guide decision-makers in the near term.

An analytical overview of the major technological, regulatory, and delivery paradigm shifts reshaping pediatric vaccine development manufacturing and uptake dynamics

The pediatric vaccine landscape is experiencing transformative shifts driven by technological breakthroughs, altered policy priorities, and new delivery paradigms that collectively redefine how protection is designed, produced, and delivered. Advances in recombinant and conjugate technologies have enabled broader antigen coverage and improved immunogenicity, allowing combination vaccines to reduce clinic visits and streamline immunization schedules. Concurrently, manufacturers are adopting modular and flexible production approaches to respond faster to demand fluctuations and to support regionally localized supply chains.

On the policy side, there is a visible push toward harmonized regulatory pathways and accelerated approval frameworks to shorten time-to-market for vaccines that address high-burden pediatric diseases. Procurement strategies are also evolving; purchasers are increasingly weighing total cost of ownership, supply assurance clauses, and lifecycle services such as training and cold chain support. Digital health and immunization registries are beginning to underpin more targeted outreach and coverage monitoring, enhancing the ability to measure real-world impact and to tailor campaigns to persistent gaps. Public trust and communication strategies remain critical, with health authorities and manufacturers investing in transparent safety communication and community engagement to maintain high uptake across diverse populations.

A clear-eyed assessment of how recent tariff measures have influenced supply chain decisions procurement strategies and the geographic distribution of pediatric vaccine production

Trade policy changes announced in 2025, including new tariff measures affecting pharmaceuticals and biologics inputs, have had a cumulative impact on pediatric vaccine value chains by amplifying cost pressures, encouraging supplier diversification, and accelerating nearshoring conversations. Raw materials such as specialized adjuvants, consumables for aseptic filling, and single-use bioreactor components became focal points for procurement teams seeking alternative sourcing strategies to mitigate tariff exposure. As a result, manufacturers and procurers have re-examined contractual terms and inventory strategies to sustain uninterrupted immunization programs.

In response, some producers have shifted investments toward regional manufacturing hubs to reduce cross-border tariff risk and to shorten lead times. This strategic relocation has implications for regulatory convergence and workforce development in host regions, because establishing biologics-capable facilities demands skilled personnel and compliance with stringent quality frameworks. For purchasers, the tariff environment has heightened the importance of transparent landed cost analyses and collaborative risk-sharing arrangements with suppliers. Ultimately, these effects have reinforced the need for scenario-based planning, where procurement teams and policy-makers evaluate trade policy contingencies alongside public health priorities to preserve immunization access for vulnerable pediatric populations.

Comprehensive segmentation insights connecting product types disease targets technologies end-user channels and age cohorts to strategic clinical and commercial implications

Segmentation analysis reveals how distinct product, disease, technology, end-user, and age-group categories drive differentiated development and delivery considerations across pediatric immunization programs. Based on Vaccine Type, market is studied across Hexavalent, Monovalent, Pentavalent, and Quadrivalent; combination vaccines such as hexavalent formulations emphasize programmatic convenience and schedule compression, while monovalent products retain strategic relevance for targeted outbreak responses and booster strategies. Based on Disease, market is studied across DTP, Hepatitis B, Hib, Measles, Pneumococcal, Polio, and Rotavirus. The DTP is further studied across Diphtheria, Pertussis, and Tetanus; disease-specific dynamics-such as serotype diversity in pneumococcal disease or genotypic variation in rotavirus-inform antigen selection and surveillance priorities.

Based on Technology, market is studied across Conjugate, Inactivated, Live Attenuated, Recombinant, and Subunit. The Conjugate is further studied across Polysaccharide Conjugate and Protein Conjugate. The Inactivated is further studied across Toxoid and Viral. The Live Attenuated is further studied across Bacterial and Viral. The Recombinant is further studied across Mammalian Cell Culture and Yeast Based. The Subunit is further studied across Peptide Subunit and Protein Subunit; these technological distinctions have direct implications for manufacturing complexity, cold chain requirements, and immunogenicity profiles, shaping both R&D prioritization and capital expenditure decisions. Based on End User, market is studied across Clinics, Hospitals, Immunization Centers, and Pharmacies. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies; distribution and training investments need to align with the dominant end-user channels in a given geography to ensure timely availability and correct administration practices. Based on Age Group, market is studied across Adolescents, Children, Infants, Neonates, and Toddlers, and tailoring formulation, dosing regimen, and delivery mechanisms to the physiological and programmatic needs of each age cohort remains a core determinant of clinical adoption and program success.

Interacting across these segmentation axes, certain patterns emerge: combination vaccines and conjugate technologies trend toward integrated programmatic value, whereas recombinant and subunit platforms offer flexible upgrade pathways for antigenic modification. End-user distribution preferences condition packaging and presentation choices, and age-group specific requirements drive formulation constraints and stability demands. Recognizing these layered segmentation realities enables stakeholders to prioritize product portfolios and operational investments that match clinical needs and delivery channel realities.

Regionally differentiated intelligence on regulatory harmonization manufacturing capacity and programmatic priorities across varied global geographies that shape vaccine access and supply

Regional dynamics exert a decisive influence on vaccine strategy, shaping manufacturing footprints, regulatory timelines, and programmatic deployment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory agility and established immunization infrastructure support rapid introduction of combination products, while public and private payers increasingly emphasize value-based procurement and supply assurance mechanisms. Supply chain nodes in North and Latin America also prioritize cold chain optimization and data-driven coverage monitoring to address urban-rural disparities.

Within Europe, Middle East & Africa, heterogeneity in regulatory frameworks and procurement capacity creates a dual imperative: harmonize standards to enable efficient market entry, and strengthen local manufacturing and distribution capabilities to close access gaps. International partnerships and donor programs continue to play a vital role in many jurisdictions, necessitating alignment between global suppliers and regional program needs. In the Asia-Pacific, manufacturing scale and investment in biologics capability are significant drivers of global supply, while rising domestic demand and government-led manufacturing incentives are accelerating capacity expansion. Across all regions, investment in digital registries and supply chain transparency is improving demand forecasting and immunization coverage measurement, enabling more targeted interventions and better allocation of limited resources.

Strategic company-level perspective revealing how manufacturers are aligning technology investments supply resilience and stakeholder partnerships to sustain pediatric vaccine leadership

Company strategies in the pediatric vaccine space are converging toward three priority themes: technological differentiation, supply chain resilience, and collaborative engagement with public health systems. Leading biological producers are investing to broaden their combination and conjugate portfolios while extending capabilities in recombinant and subunit platforms that facilitate antigen updates and scalable manufacture. Concurrently, players are pursuing capacity enhancements, including modular fill-finish lines and geographically distributed manufacturing nodes, to mitigate disruption risk and to meet country-level sourcing preferences.

Industry participants are also deepening partnerships with contract development and manufacturing organizations, academic centers, and public-private consortia to accelerate development timelines and expand local production. Commercial approaches increasingly bundle product supply with value-added services such as cold chain strengthening, training for health workers, and data sharing agreements that support coverage monitoring. Pricing strategies reflect a balance between ensuring affordability for public programs and preserving margins that sustain ongoing R&D. For smaller or regional manufacturers, focusing on niche disease targets, cost-effective platforms, or specialized distribution agreements offers defensible positions that complement the broader strategies of multinational producers. Overall, corporate success is tied to the ability to integrate scientific innovation with pragmatic manufacturing and stakeholder collaboration.

Actionable recommendations that integrate product innovation supply diversification pricing strategies and stakeholder engagement to drive sustainable pediatric immunization outcomes

Industry leaders should pursue a coordinated set of actions that blend innovation, operational rigor, and stakeholder alignment to improve pediatric vaccine access and program outcomes. First, prioritize development of combination and conjugate formulations that reduce administration complexity and improve adherence, while ensuring that manufacturing investments support flexible production across multiple platforms. Second, invest in diversified sourcing strategies and regional manufacturing options to shield programs from external trade shocks and to meet procurement preferences for local supply assurance.

Third, strengthen end-user engagement by pairing product launches with training, cold chain support, and integration into digital immunization registries to enhance uptake and monitoring. Fourth, adopt tailored pricing and contracting models that balance affordability for public purchasers with incentives for sustained R&D investment, including outcome-based agreements and volume-linked supply commitments. Fifth, deepen collaborations with public health agencies, global donors, and clinical networks to align clinical trial design, post-marketing surveillance, and safety communication strategies. By executing these steps in parallel, companies and health systems can accelerate access to effective pediatric immunizations while building the operational foundations required for long-term program stability.

A transparent research methodology describing primary interviews secondary synthesis and analytical safeguards used to produce validated insights on pediatric vaccine dynamics

The research underpinning this executive summary synthesizes primary stakeholder input with rigorous secondary analysis to ensure balanced and verifiable insights. Primary data were gathered through structured interviews with vaccine developers, manufacturing leaders, procurement specialists, clinical program managers, and policy-makers, which provided real-world perspectives on supply chain constraints, regulatory priorities, and adoption barriers. These qualitative inputs were triangulated with secondary sources including regulatory guidance documents, peer-reviewed literature on vaccine technologies, publicly disclosed corporate filings related to capacity investments, and global immunization program reports to validate observed trends.

Analytical methods included thematic coding of interview data to identify recurring challenges and strategic responses, comparative technology assessment to evaluate platform advantages and constraints, and scenario analysis to explore implications of trade policy and manufacturing shifts. Quality assurance measures involved cross-validation of key findings with domain experts and review of technical assumptions against authoritative clinical and regulatory references. Limitations of the methodology include potential variability in stakeholder perspectives across jurisdictions and the rapidly evolving nature of vaccine science; nonetheless, the combination of primary and secondary inputs offers a robust foundation for the strategic conclusions presented herein.

A concise conclusion synthesizing technological promise operational constraints and strategic priorities that will determine pediatric immunization success

In summary, pediatric vaccines sit at the intersection of accelerating scientific capability and entrenched operational realities. Technological progress in conjugate, recombinant, and combination formulations presents clear pathways to broaden protection while simplifying schedules, yet programmatic adoption hinges on reliable supply, regulatory alignment, and sustained public trust. Trade policy developments and tariff shifts have highlighted the fragility of some global supply linkages and are catalyzing investment in regional capacity, which will reshape procurement relationships and regulatory collaboration in the coming years.

As stakeholders navigate this environment, the most successful strategies will combine targeted product portfolios with resilient manufacturing footprints, thoughtful contracting approaches, and integrated end-user support. Decision-makers who prioritize alignment across R&D, manufacturing, procurement, and program delivery will be best positioned to convert scientific advances into durable public health impact for infants, children, and adolescents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pediatric Vaccines Market, by Vaccine Type

  • 8.1. Hexavalent
  • 8.2. Monovalent
  • 8.3. Pentavalent
  • 8.4. Quadrivalent

9. Pediatric Vaccines Market, by Disease

  • 9.1. DTP
    • 9.1.1. Diphtheria
    • 9.1.2. Pertussis
    • 9.1.3. Tetanus
  • 9.2. Hepatitis B
  • 9.3. Hib
  • 9.4. Measles
  • 9.5. Pneumococcal
  • 9.6. Polio
  • 9.7. Rotavirus

10. Pediatric Vaccines Market, by Technology

  • 10.1. Conjugate
    • 10.1.1. Polysaccharide Conjugate
    • 10.1.2. Protein Conjugate
  • 10.2. Inactivated
    • 10.2.1. Toxoid
    • 10.2.2. Viral
  • 10.3. Live Attenuated
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Recombinant
    • 10.4.1. Mammalian Cell Culture
    • 10.4.2. Yeast Based
  • 10.5. Subunit
    • 10.5.1. Peptide Subunit
    • 10.5.2. Protein Subunit

11. Pediatric Vaccines Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Immunization Centers
  • 11.4. Pharmacies
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies

12. Pediatric Vaccines Market, by Age Group

  • 12.1. Adolescents
  • 12.2. Children
  • 12.3. Infants
  • 12.4. Neonates
  • 12.5. Toddlers

13. Pediatric Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pediatric Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pediatric Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pediatric Vaccines Market

17. China Pediatric Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca plc
  • 18.6. Bharat Biotech International Ltd.
  • 18.7. Biological E. Limited
  • 18.8. GlaxoSmithKline plc (GSK)
  • 18.9. Johnson & Johnson
  • 18.10. Merck & Co., Inc.
  • 18.11. Moderna, Inc.
  • 18.12. Novavax, Inc.
  • 18.13. Pfizer Inc.
  • 18.14. PT Bio Farma
  • 18.15. Sanofi S.A.
  • 18.16. Serum Institute of India Pvt. Ltd.
  • 18.17. Shenzhen Kangtai Biological Products Co., Ltd.
  • 18.18. Sinovac Biotech Ltd.
  • 18.19. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEDIATRIC VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEDIATRIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. GCC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 289. GCC PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 292. GCC PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 293. GCC PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 294. GCC PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 295. GCC PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GCC PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 330. G7 PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 331. G7 PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. G7 PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 333. G7 PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 334. G7 PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. G7 PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 336. G7 PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 337. G7 PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 338. G7 PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 339. G7 PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 340. G7 PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. G7 PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 342. G7 PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 343. G7 PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 344. G7 PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 345. NATO PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 346. NATO PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (US